Detail of "698387-09-6"

CAS Number:
698387-09-6
Name:
2-Butenamide,N-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-,(2E)-
Superlist Name:
Neratinib
Molecular Structure:
Formula:
C₃₀H₂₉ClN₆O₃
Molecular Weight:
557.04
Synonyms:
(E)-N-[4-[3-Chloro-4-[(2-pyridinyl)methoxy]anilino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide;(E)-N-[4-[[3-Chloro-4-((pyridin-2-yl)methoxy)phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)-2-butenamide;HKI 272;HKI-272(Neratinib);
Density:
1.337 g/cm³
Boiling Point:
756.97 °C at 760 mmHg
Flash Point:
411.601 °C

Famous Chemical Enterprises

Livzon
Total
Shell
Dupont
Exxonmobil
Akzonobel
Basf
Bayer
BP

Other Products

Supplier Location
Supplier Location
- China (Mainland)(22)
- United States(1)
Business Type
Business Type
- Lab/Research institutions(8)
- Manufacturers(0)
- Trading Company(12)
Certificates
Certificates
- ISO(1)
- Production License (0)

Please post your buying leads>>

Display：

Manufacturer
Enterprise Authentication
Suppiers of more reward points first
New supplier

Please post your buying leads,so that our qualified suppliers will soon contact you!
*Required Fields

Reference

Epidermal Growth Factor Receptor Inhibitors in Development for the Treatment of Non-Small Cell Lung Cancer: All Rights Reserved. Epidermal Growth Factor Receptor Inhibitors in Development for the Treatment of Non-Small Cell Lung Cancer. Heymach, John V.; Nilsson, Monique; Blumenschein, George; Papadimitrakopoulou, Vassiliki; Herbst, Roy (Department of Thoracic/Head, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030-4009, USA). Clinical Cancer Research, 12(14, Pt. 2), 4441s-4445s (English) 2006 American Association for Cancer Research. CODEN: CCREF4. ISSN: 1078-0432. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacology) Section cross-reference(s): 15 A review. The epidermal growth factor receptor (EGFR) inhibitors erlotinib, gefitinib, and cetuximab have undergone extensive clin. testing and have established clin. activity in non-small cell lung cancer and other types of solid tumors. A no. of newer inhibitors are currently in clin. development with different spectra of activity or mechanisms of receptor inhibition. These include monoclonal antibodies, such as panitumumab and matuzumab; dual inhibitors of EGFR and vascular endothelial growth factor receptor, such as ZD6474 and AEE788; inhibitors of multiple EGFR family members, such as lapatinib; and irreversible inhibitors, such as canertinib and HKI272. Preclin. studies suggest that several of these agents may have activity in tumors refractory to erlotinib or gefitinib. Among these agents, ZD6474 has undergone the most extensive clin. testing. The antitumor activity of ZD6474 in these two randomized phase II clin. trials in patients with non-small cell lung cancer was felt to be sufficiently promising to warrant phase III clin. testing. Several of the other EGFR inhibitors are also undergoing advanced clin. testing, either alone or in combination with other agents. EGFR has now been validated as a clin. relevant target, and several different types of agents inhibiting this receptor are currently in development. Future research will be needed to elucidate the role of these agents in patients with EGFR inhibitor-naive and EGFR inhibitor-refractory disease, to define the mol. characteristics that predict response, and to det. whether these drugs should be used in combination with other targeted agents or chemotherapy.Except for chemicals metioned above, 497839-62-0 and 698387-09-6 are also used. .

Detail of "698387-09-6"

2-Butenamide,N-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-,(2E)-

Famous Chemical Enterprises

Related products

Other Products

Supplier Location

Business Type

Certificates

CAS No.698387-09-6 Neratinib

CAS No.698387-09-6 Neratinib

CAS No.698387-09-6 Neratinib

CAS No.698387-09-6 Neratinib

CAS No.698387-09-6 Neratinib

CAS No.698387-09-6 Neratinib

CAS No.698387-09-6 Neratinib

CAS No.698387-09-6 Neratinib

CAS No.698387-09-6 Neratinib

CAS No.698387-09-6 Neratinib

CAS No.698387-09-6 Neratinib

CAS No.698387-09-6 Neratinib

CAS No.698387-09-6 Neratinib

CAS No.698387-09-6 Neratinib

CAS No.698387-09-6 Neratinib

CAS No.698387-09-6 Neratinib

CAS No.698387-09-6 Neratinib

CAS No.698387-09-6 Neratinib

CAS No.698387-09-6 Neratinib

CAS No.698387-09-6 Neratinib

CAS No.698387-09-6 Neratinib

CAS No.698387-09-6 Neratinib

CAS No.698387-09-6 Neratinib

Reference